Updates of Pathogenesis, Diagnosis, and Treatment of Immune Thrombocytopenia

Maged Naser, Mohamed M. Nasr, Lamia H. Shehata

Abstract


Primary immune thrombocytopenia is an autoimmune disorder associated with a decreased  prephiral blood platelet count. The phenotype is variable with a few instances struggling no bleeding while others have extreme bleeding which may be deadly. Variability in clinical  behaviour and remedy responses reflects its complicated pathophysiology. Traditionally the  management has relied heavily on immune suppression. latest studies have shown that the older empirical immune suppressants fail to adjust the natural history of the complaint and are associated with a bad exceptional life for patients. More recent remedies, the thrombopoietin receptor agonists, have converted ITP care. they've excessive efficacy, are nicely tolerated and ameliorate cases ’ high-quality of lifestyles. An extra expertise of the underpinning pathophysiology of this  criticism has helped development more recent targeted curatives. These consist of inhibitors of the neonatal Fc receptor inhibitors, Bruton tyrosine kinase and supplement pathway. Then we bandy the mechanisms underlying ITP and the new method to ITP care.

Keywords


Immune Thrombocytopenia, Immune Suppression, Thrombopoietin Receptor Agonists

Full Text:

PDF

References


-Hayter, Scott M., and Matthew C. Cook. "Updated assessment of the prevalence, spectrum and case definition of autoimmune disease." Autoimmunity reviews 11.10 (2012): 754-765.‏

-Cines, Douglas B., and Victor S. Blanchette. "Immune thrombocytopenic purpura." New England Journal of Medicine 346.13 (2002): 995-1008.‏

-Provan, Drew, et al. "Updated international consensus report on the investigation and management of primary immune thrombocytopenia." Blood advances 3.22 (2019): 3780-3817.‏

-Harrington, William J., et al. "Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura." The Journal of laboratory and clinical medicine 38.1 (1951): 1-10.‏

-Gernsheimer, Terry, et al. "Mechanisms of response to treatment in autoimmune thrombocytopenic purpura." New England Journal of Medicine 320.15 (1989): 974-980.‏

-Olsson, Bob, et al. "T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura." Nature medicine 9.9 (2003): 1123-1124.‏

-Semple, John W., and John Freedman. "Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia." Transfusion Medicine Reviews 9.4 (1995): 327-338.‏

-Semple, John W., et al. "An update on the pathophysiology of immune thrombocytopenia." Current opinion in hematology 27.6 (2020): 423-429.‏

-Audia, Sylvain, et al. "Immune thrombocytopenia: recent advances in pathogenesis and treatments." Hemasphere 5.6 (2021): e574.‏

-Swinkels, Maurice, et al. "Emerging concepts in immune thrombocytopenia." Frontiers in immunology 9 (2018): 880.‏

-Morante-Palacios, Octavio, et al. "Tolerogenic dendritic cells in autoimmunity and inflammatory diseases." Trends in immunology 42.1 (2021): 59-75.‏

-Kissel, Karin, et al. "Human platelets target dendritic cell differentiation and production of proinflammatory cytokines." Transfusion 46.5 (2006): 818-827.‏

-Catani, Lucia, et al. "Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes." Experimental hematology 34.7 (2006): 879-887.‏

-Chapman, Lesley M., et al. "Platelets present antigen in the context of MHC class I." The Journal of Immunology 189.2 (2012): 916-923.‏

-Zufferey, Anne, et al. "Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets." Blood advances 1.20 (2017): 1773-1785.‏

-Marcoux, Genevieve, et al. "Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules." Blood, The Journal of the American Society of Hematology 138.25 (2021): 2607-2620.‏

-Zanna, Mohammed Yusuf, et al. "Review of dendritic cells, their role in clinical immunology, and distribution in various animal species." International journal of molecular sciences 22.15 (2021): 8044.‏

-Catani, Lucia, et al. "Decreased expression of indoleamine 2, 3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia." Annals of hematology 92 (2013): 67-78.‏

-Xu, Shu-qian, et al. "Decreased indoleamine 2, 3-dioxygenase expression in dendritic cells and role of indoleamine 2, 3-dioxygenase-expressing dendritic cells in immune thrombocytopenia." Annals of hematology 91 (2012): 1623-1631.‏

-Saito, Akio, et al. "Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori‐associated immune thrombocytopenia." European journal of haematology 88.4 (2012): 340-349.‏

-Clancy, Robert. "Cellular immunity to autologous platelets and serum-blocking factors in idiopathic thrombocytopenic purpura." The Lancet 299.7740 (1972): 6-9.‏

-Calandra, Thierry, and Thierry Roger. "Macrophage migration inhibitory factor: a regulator of innate immunity." Nature reviews immunology 3.10 (2003): 791-800.‏

-Zufferey, Anne, Rick Kapur, and John W. Semple. "Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)." Journal of clinical medicine 6.2 (2017): 16.‏

-Semple, John W., et al. "Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and anti-platelet T-cell reactivity." (1996): 4245-4254.‏

-Semple, John W., and Rick Kapur. "Platelet immunology from the inside out." ISBT Science Series 15.3 (2020): 315-319.‏

-Karolczak, Kamil, and Cezary Watala. "Blood platelets as an important but underrated circulating source of TGFβ." International journal of molecular sciences 22.9 (2021): 4492.‏

-Wang, Jiaan‐Der, et al. "Reduced expression of transforming growth factor‐β1 and correlated elevation of interleukin‐17 and interferon‐γ in pediatric patients with chronic primary immune thrombocytopenia (ITP)." Pediatric blood & cancer 57.4 (2011): 636-640.‏

-Andersson, Per‐Ola, Anna Olsson, and Hans Wadenvik. "Reduced transforming growth factor‐β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura." British journal of haematology 116.4 (2002): 862-867.‏

-Andersson, P. O., et al. "A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura." Annals of Hematology 79 (2000): 507-513.‏

-Panitsas, Fotios P., et al. "Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response." Blood 103.7 (2004): 2645-2647.‏

-Roncarolo, Maria Grazia, et al. "The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases." Immunity 49.6 (2018): 1004-1019.‏

-Najaoui, Abderrahim, et al. "Autoantibody‐mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)." European journal of haematology 88.2 (2012): 167-174.‏

-Kurata, Y., et al. "Platelet‐associated complement in chronic ITP." British journal of haematology 60.4 (1985): 723-733.‏

-Cheloff, Abraham Z., David J. Kuter, and Hanny Al‐Samkari. "Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features." Research and Practice in Thrombosis and Haemostasis 4.5 (2020): 807-812.‏

-Broome, Catherine M., et al. "Long-term safety and efficacy of sutimlimab in patients with chronic immune thrombocytopenia." Blood 136 (2020): 14-15.‏

-Pross, H. F., and Ml Jondal. "Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes." Clinical and experimental immunology 21.2 (1975): 226.‏

-Kiessling, R., et al. "„Natural” ︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell." European journal of immunology 5.2 (1975): 117-121.‏

-Semple, John W., Suzanne Bruce, and John Freedman. "Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura." American journal of hematology 37.4 (1991): 258-262.‏

-Ebbo, M., et al. "NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia." Clinical Immunology 177 (2017): 18-28.‏

-El-Rashedi, Farida Hussein, et al. "Study of CD4+, CD8+, and natural killer cells (CD16+, CD56+) in children with immune thrombocytopenic purpura." Hematology/oncology and stem cell therapy 10.1 (2017): 8-14.‏

-Paolini, Rossella, et al. "NK cells and interferons." Cytokine & growth factor reviews 26.2 (2015): 113-120.‏

-Cook, Kevin D., Hannah C. Kline, and Jason K. Whitmire. "NK cells inhibit humoral immunity by reducing the abundance of CD4+ T follicular helper cells during a chronic virus infection." Journal of Leucocyte Biology 98.2 (2015): 153-162.‏

-Rydyznski, Carolyn E., et al. "Affinity maturation is impaired by natural killer cell suppression of germinal centers." Cell reports 24.13 (2018): 3367-3373.‏

-Hymes, Kenneth B., and Simon Karpatkin. "In vitro suppressor T lymphocyte dysfunction in autoimmune thrombocytopenic purpura associated with a complement‐fixing antibody." British journal of haematology 74.3 (1990): 330-335.‏

-Liu, Bin, et al. "Abnormality of CD4+ CD25+ regulatory T cells in idiopathic thrombocytopenic purpura." European journal of haematology 78.2 (2007): 139-143.‏

-Li, Xiaojuan, et al. "Defective regulatory B-cell compartment in patients with immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 120.16 (2012): 3318-3325.‏

-Denys, Agnes, et al. "Evidence for a dual mechanism for IL-10 suppression of TNF-α production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-κB in primary human macrophages." The Journal of Immunology 168.10 (2002): 4837-4845.‏

-Armstrong, Lynne, Nicola Jordan, and Ann Millar. "Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes." Thorax 51.2 (1996): 143.‏

-Bao, Weili, et al. "Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents." Blood, The Journal of the American Society of Hematology 116.22 (2010): 4639-4645.‏

-Aslam, Rukhsana, et al. "Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells." British journal of haematology 173.1 (2016): 159-160.‏

-Gabrilovich, Dmitry I., and Srinivas Nagaraj. "Myeloid-derived suppressor cells as regulators of the immune system." Nature reviews immunology 9.3 (2009): 162-174.‏

-Highfill, Steven L., et al. "Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–dependent mechanism that is up-regulated by interleukin-13." Blood, The Journal of the American Society of Hematology 116.25 (2010): 5738-5747.‏

-Hou, Yu, et al. "High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 127.12 (2016): 1587-1597.‏

-Aslam, Rukhsana, et al. "Intravenous immunoglobulin treatment of spleen cells from patients with immune thrombocytopenia significantly increases the percentage of myeloid-derived suppressor cells." British journal of haematology 181.2 (2018): 262-264.‏

-Hou, M., et al. "Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura." European journal of haematology 55.5 (1995): 307-314.‏

-McMillan, Robert. "Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production." Hematology/Oncology Clinics 23.6 (2009): 1163-1175.‏

-Yu, Lingjia, et al. "Biomarkers for immune thrombocytopenia." Biomarker Research 3 (2015): 1-4.‏

-Porcelijn, Leendert, et al. "Evolution and utility of antiplatelet autoantibody testing in patients with immune thrombocytopenia." Transfusion Medicine Reviews 34.4 (2020): 258-269.‏

-Wu, Zhong, et al. "Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals." International journal of hematology 96 (2012): 588-593.‏

-Moulis, Guillaume, et al. "Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort." American journal of hematology 92.6 (2017): 493-500.‏

-Mahévas, Matthieu, et al. "Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia." American journal of hematology 88.10 (2013): 858-861.‏

-Wang, Yan-ming, et al. "The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia." Hematology 25.1 (2020): 139-144.‏

-Baysal, Mehmet, et al. "Could antinuclear antibody positivity be a factor affecting treatment response in immune thrombocytopenia patients on eltrombopag?." Turkish Journal of Hematology 39.1 (2022): 38.‏

-Bernlochner, Isabell, et al. "Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome." European heart journal 36.45 (2015): 3202-3210.‏

-Benlachgar, Naoufal, et al. "Immature platelets: a review of the available evidence." Thrombosis research 195 (2020): 43-50.‏

-Jeon, Kibum, et al. "Immature platelet fraction: a useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery." Medicine 99.7 (2020).‏

-Ruisi, Mary M., et al. "Stability of measurement of the immature platelet fraction." American journal of hematology 85.8 (2010): 622-624.‏

-Barsam, Sarah J., et al. "Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 117.21 (2011): 5723-5732.‏

-Blandinières, Adeline, et al. "Usefulness of immature platelet fraction measurement for diagnosis and monitoring of iron deficiency associated thrombocytopenia: about two cases." Annales de Biologie Clinique. Vol. 78. No. 4. 2020.‏

-Negro, Federica, et al. "Impact of gender on immature platelet count and its relationship with coronary artery disease." Journal of Thrombosis and Thrombolysis 49 (2020): 511-521.‏

-Verdoia, Monica, et al. "Impact of aging on immature platelet count and its relationship with coronary artery disease." Platelets 31.8 (2020): 1060-1068.‏

-Hong, Hong, Wenbin Xiao, and Robert W. Maitta. "Steady increment of immature platelet fraction is suppressed by irradiation in single-donor platelet components during storage." PloS one 9.1 (2014): e85465.‏

-Abe, Yasunori, et al. "A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF)." Thrombosis research 118.4 (2006): 463-469.‏

-Adly, Amira Abdel Moneam, et al. "Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia." Platelets 26.7 (2015): 645-650.‏

-McDonnell, Alicia, et al. "Utility of the immature platelet fraction in pediatric immune thrombocytopenia: Differentiating from bone marrow failure and predicting bleeding risk." Pediatric Blood & Cancer 65.2 (2018): e26812.‏

-Frelinger III, A. L., et al. "Platelet function in ITP, independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity." Thrombosis and haemostasis 118.01 (2018): 143-151.‏

-Tremaroli, Valentina, and Fredrik Bäckhed. "Functional interactions between the gut microbiota and host metabolism." Nature 489.7415 (2012): 242-249.‏

-Pereira, Karla Nunes, et al. "Diagnostic characteristics of immature platelet fraction for the assessment of immune thrombocytopenia." Thrombosis Research 202 (2021): 125-127.‏

-Ali, Imtiaz, Ciaren Graham, and Nina C. Dempsey-Hibbert. "Immature platelet fraction as a useful marker in the etiological determination of thrombocytopenia." Experimental Hematology 78 (2019): 56-61.‏

-Serrando, M., et al. "Clinical significance of IPF% measurement in diagnosing thrombocytopenic disorders: distinguishing primary immune thrombocytopenia from other disorders." International Journal of Laboratory Hematology 38.3 (2016): e65-e68.‏

-Yang, Lei, et al. "Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 116.20 (2010): 4307-4316.‏

-Gu, Dongsheng, et al. "Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia." Human immunology 71.6 (2010): 586-591.‏

-Ku, Fan‐Chen, et al. "Stromal‐derived factor‐1 gene variations in pediatric patients with primary immune thrombocytopenia." European Journal of Haematology 90.1 (2013): 25-30.‏

-Wang, Jian-Feng, Zhong-Ying Liu, and Jerome E. Groopman. "The α-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion." Blood, The Journal of the American Society of Hematology 92.3 (1998): 756-764.‏

-Saeidi, Sajedeh, et al. "Is there a relationship between CXCR4 gene expression and prognosis of immune thrombocytopenia in children?." Indian Journal of Hematology and Blood Transfusion 33 (2017): 216-221.‏

-Chevalier, Nina, et al. "CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses." The Journal of Immunology 186.10 (2011): 5556-5568.‏

-Ansel, K. Mark, Ruth BS Harris, and Jason G. Cyster. "CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity." Immunity 16.1 (2002): 67-76.‏

-Alvarez, Enrique, et al. "CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions." Multiple Sclerosis Journal 19.9 (2013): 1204-1208.‏

-Jernås, Margareta, et al. "MicroRNA regulate immunological pathways in T-cells in immune thrombocytopenia (ITP)." Blood, The Journal of the American Society of Hematology 121.11 (2013): 2095-2098.‏

-Li, Jian-Qin, et al. "MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia." American Journal of Translational Research 7.4 (2015): 772.‏

-Zhang, Lin, et al. "Immune status and chemokine C receptor 7 expression in primary in patients with immune thrombocytopenia." Turkish Journal of Hematology 39.1 (2022): 29.‏

-Schneider, Pascal, et al. "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth." The Journal of experimental medicine 189.11 (1999): 1747-1756.‏

-Moore, Paul A., et al. "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator." Science 285.5425 (1999): 260-263.‏

-Huard, Bertrand, et al. "T cell costimulation by the TNF ligand BAFF." The Journal of Immunology 167.11 (2001): 6225-6231.‏

-Ye, Qunrui, et al. "BAFF binding to T cell‐expressed BAFF‐R co-stimulates T cell proliferation and alloresponses." European journal of immunology 34.10 (2004): 2750-2759.‏

-Huard, Bertrand, et al. "BAFF production by antigen‐presenting cells provides T cell co‐stimulation." International immunology 16.3 (2004): 467-475.‏

-Zhu, Xiao-juan, et al. "The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 114.26 (2009): 5362-5367.‏

-Khalifa, Khaled AE, et al. "Expression of B-cell activating factor in pediatric patients with immune thrombocytopenia: A single institutional series and review of literature." Journal of Immunoassay and Immunochemistry 44.1 (2023): 41-55.‏

-Wu, Boting, et al. "CXCL13, CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia." Journal of Translational Medicine 13 (2015): 1-7.‏

-Velo-García, Alba, Sara Guerreiro Castro, and David A. Isenberg. "The diagnosis and management of the haematologic manifestations of lupus." Journal of autoimmunity 74 (2016): 139-160.‏

-Provan, Drew, et al. "International consensus report on the investigation and management of primary immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 115.2 (2010): 168-186.‏

-Aringer, Martin, et al. "2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus." Arthritis & rheumatology 71.9 (2019): 1400-1412.‏

-Dinarello, Charles A. "Interleukin-1 in the pathogenesis and treatment of inflammatory diseases." Blood, The Journal of the American Society of Hematology 117.14 (2011): 3720-3732.‏

-Calvani, Nicola, et al. "Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18." Autoimmunity reviews 4.8 (2005): 542-548.‏

-Liang, Dong, et al. "Imbalance of interleukin 18 and interleukin 18 binding protein in patients with lupus nephritis." Cell Mol Immunol 3.4 (2006): 303-306.‏

-Tucci, Marco, et al. "Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin‐18." Arthritis & Rheumatism 58.1 (2008): 251-262.‏

-Shan, Ning‐ning, et al. "Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura." British journal of haematology 144.5 (2009): 755-761.‏

-Sutton, Caroline, et al. "A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis." The Journal of experimental medicine 203.7 (2006): 1685-1691.‏

-Acosta-Rodriguez, Eva V., et al. "Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells." Nature immunology 8.9 (2007): 942-949.‏

-Zhan, Yanxia, et al. "Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia." Annals of translational medicine 9.3 (2021).‏

-Sarrand, Julie, and Muhammad Soyfoo. "Involvement of il-33 in the pathophysiology of systemic lupus erythematosus." International journal of molecular sciences 23.6 (2022): 3138.‏

-Andersson, J. J. A. P. "Cytokines in idiopathic thrombocytopenic purpura (ITP)." Acta Paediatrica 87 (1998): 61-64.‏

-Esteller, Manel. "Non-coding RNAs in human disease." Nature reviews genetics 12.12 (2011): 861-874.‏

-Allegra, Alessandro, et al. "Circular RNA as a novel biomarker for diagnosis and prognosis and potential therapeutic targets in multiple myeloma." Cancers 14.7 (2022): 1700.‏

-Allegra, Alessandro, et al. "Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer." International journal of oncology 41.6 (2012): 1897-1912.‏

-Warth, Sebastian C., et al. "Induced miR‐99a expression represses Mtor cooperatively with miR‐150 to promote regulatory T‐cell differentiation." The EMBO journal 34.9 (2015): 1195-1213.‏

-Zhao, Haifeng, et al. "Reduced MIR 130 A is involved in primary immune thrombocytopenia via targeting TGFB 1 and IL 18." British journal of haematology 166.5 (2014): 767-773.‏

-Chang, Mei, et al. "Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro." Blood 102.3 (2003): 887-895.‏

-Wang, Juan, et al. "Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome." Immunologic research 64 (2016): 489-496.‏

-Liu, Wen-Jun, et al. "Role of platelet function and platelet membrane glycoproteins in children with primary immune thrombocytopenia." Molecular medicine reports 14.3 (2016): 2052-2060.‏

-Zhao, Yuerong, et al. "The Extensive Regulation of MicroRNA in Immune Thrombocytopenia." Clinical and Applied Thrombosis/Hemostasis 28 (2022): 10760296221093595.‏

-Fan, Zhenwei, et al. "Systematic identification of lncRNA-associated ceRNA networks in immune thrombocytopenia." Computational and Mathematical Methods in Medicine 2020 (2020).‏

-Tremaroli, Valentina, and Fredrik Bäckhed. "Functional interactions between the gut microbiota and host metabolism." Nature 489.7415 (2012): 242-249.‏

-Allegra, A., et al. "Role of the microbiota in haematologic malignancies." Neth. J. Med 77.2 (2019): 67-80.‏

-Allegra, Alessandro, et al. "Interactions between the MicroRNAs and microbiota in cancer development: Roles and therapeutic opportunities." Cancers 12.4 (2020): 805.‏

-Innao, Vanessa, et al. "New frontiers about the role of human microbiota in immunotherapy: the immune checkpoint inhibitors and CAR T-cell therapy era." International Journal of Molecular Sciences 21.23 (2020): 8902.‏

-Russell, Jordan T., et al. "Genetic risk for autoimmunity is associated with distinct changes in the human gut microbiome." Nature communications 10.1 (2019): 3621.‏

-Kouchaki, Ebrahim, et al. "Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial." Clinical nutrition 36.5 (2017): 1245-1249.‏

-Maeda, Yuichi, and Kiyoshi Takeda. "Role of gut microbiota in rheumatoid arthritis." Journal of clinical medicine 6.6 (2017): 60.

-Zhang, Xuewu, et al. "Gut microbiome and metabolome were altered and strongly associated with platelet count in adult patients with primary immune thrombocytopenia." Frontiers in microbiology 11 (2020): 1550.

-Johnsen, Jill. "Pathogenesis in immune thrombocytopenia: new insights." Hematology 2010, the American Society of Hematology Education Program Book 2012.1 (2012): 306-312.

-Cines, Douglas B., Adam Cuker, and John W. Semple. "Pathogenesis of immune thrombocytopenia." La Presse Médicale 43.4 (2014): e49-e59.

-Toltl, Lisa J., et al. "Piecing together the humoral and cellular mechanisms of immune thrombocytopenia." Seminars in thrombosis and hemostasis. Vol. 37. No. 06. © Thieme Medical Publishers, 2011.

-Panzer, Simon, et al. "Platelet‐associated immunoglobulins IgG, IgM, IgA and complement C3 in immune and nonimmune thrombocytopenic disorders." American journal of hematology 23.2 (1986): 89-99.

-Peerschke, Ellinor I., Wei Yin, and Berhane Ghebrehiwet. "Complement activation on platelets: implications for vascular inflammation and thrombosis." Molecular immunology 47.13 (2010): 2170-2175.

-Kayser, W., et al. "Platelet‐associated complement C3 in thrombocytopenic states." British journal of haematology 54.3 (1983): 353-363.

-Najaoui, Abderrahim, et al. "Autoantibody‐mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)." European journal of haematology 88.2 (2012): 167-174.

-Peerschke, Ellinor IB, et al. "Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura." British journal of haematology 148.4 (2010): 638-645.

-Verschoor, Admar, and Harald F. Langer. "Crosstalk between platelets and the complement system in immune protection and disease." Thrombosis and haemostasis 110.11 (2013): 910-919.

-Lurhuma, A. Z., H. Riccomi, and P. L. Masson. "The occurrence of circulating immune complexes and viral antigens in idiopathic thrombocytopenic purpura." Clinical and Experimental Immunology 28.1 (1977): 49.

-Trent, R. J., et al. "Immune complexes in thrombocytopenic patients: cause or effect?." British Journal of Haematology 44.4 (1980): 645-654.

-Ohali, Meli, et al. "Complement profile in childhood immune thrombocytopenic purpura: a prospective pilot study." Annals of hematology 84 (2005): 812-815.

-Forster, J., Z. Katzikadamos, and P. Zinn. "Platelet-associated IgG, IgM, and C3 in paediatric infectious disease." Helvetica Paediatrica Acta 43.5-6 (1989): 415-422.

-Ruiz-Delgado, Guillermo J., et al. "Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria." Hematology 14.1 (2009): 33-37.

-Zhu, Xiaolu, et al. "Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia." Annals of Hematology 97 (2018): 641-654.

-Sahip, Birsen, et al. "Higher interleukin 21 level is predictive of relapse in immune thrombocytopenia. Is it associated with activation of the complement system?." British Journal of Haematology 173.2 (2016): 321-323.

-Xu, Chengfeng, et al. "A polygenic stacking classifier revealed the complicated platelet transcriptomic landscape of adult immune thrombocytopenia." Molecular Therapy-Nucleic Acids 28 (2022): 477-487.

-Miltiadous, Oriana, Ming Hou, and James B. Bussel. "Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment." Blood, The Journal of the American Society of Hematology 135.7 (2020): 472-490.

-Psaila, Bethan, and James B. Bussel. "Refractory immune thrombocytopenic purpura: current strategies for investigation and management." British journal of haematology 143.1 (2008): 16-26.

-Provan, Drew, et al. "Updated international consensus report on the investigation and management of primary immune thrombocytopenia." Blood advances 3.22 (2019): 3780-3817.

-Rodeghiero, Francesco, et al. "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group." Blood, The Journal of the American Society of Hematology 113.11 (2009): 2386-2393.

-Neunert, Cindy, et al. "American Society of Hematology 2019 guidelines for immune thrombocytopenia." Blood advances 3.23 (2019): 3829-3866.

-Kim, Dong Jin, and Jae Hee Chung. "Long-term results of laparoscopic splenectomy in pediatric chronic immune thrombocytopenic purpura." Annals of surgical treatment and research 86.6 (2014): 314-318.

-Cuker, Adam, and Cindy E. Neunert. "How I treat refractory immune thrombocytopenia." Blood, The Journal of the American Societ

-Heitink-Polle, Katja MJ, et al. "Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis." Blood, The Journal of the American Society of Hematology 124.22 (2014): 3295-3307.

-Bergmann, Anke K., Rachael F. Grace, and Ellis J. Neufeld. "Genetic studies in pediatric ITP: outlook, feasibility, and requirements." Annals of hematology 89.Suppl 1 (2010): 95-103.

-Rischewski, Johannes R., et al. "Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition?." Pediatric blood & cancer 47.S5 (2006): 678-680.

-Zhao, Shasha, et al. "Chronic refractory immune thrombocytopenia is associated with variants in immune genes." Clinical and Applied Thrombosis/Hemostasis 27 (2021): 10760296211059813.

-Strowig, Till, et al. "Inflammasomes in health and disease." nature 481.7381 (2012): 278-286.

-Qiao, Jianlin, et al. "Elevated expression of NLRP3 in patients with immune thrombocytopenia." Immunologic research 64 (2016): 431-437.

-Yu, Jie, et al. "NF-κB-94ins/del ATTG genotype contributes to the susceptibility and imbalanced Th17 cells in patients with immune thrombocytopenia." Journal of immunology research 2018 (2018).

-Cooper, Nichola, et al. "Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): impact of ITP on health‐related quality of life." American journal of hematology 96.2 (2021): 199-207.

-Pavord, Sue, et al. "Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic." British Journal of Haematology 189.6 (2020): 1038-1043.

-Bradbury, Charlotte A., et al. "Mycophenolate mofetil for first-line treatment of immune thrombocytopenia." New England Journal of Medicine 385.10 (2021): 885-895.

-Kuter, David J. "New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura." European Journal of Haematology 80 (2008): 9-18.

-Li, Junzhi, et al. "Thrombocytopenia caused by the development of antibodies to thrombopoietin." Blood, The Journal of the American Society of Hematology 98.12 (2001): 3241-3248.

-Ghanima, Waleed, et al. "Thrombopoietin receptor agonists: ten years later." Haematologica 104.6 (2019): 1112.

-Al-Samkari, Hanny, and David J. Kuter. "Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia." Therapeutic advances in hematology 10 (2019): 2040620719841735.

-Kuter, David J. "Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia." Annual review of medicine 60 (2009): 193-206.

-Kuter, David J., et al. "Romiplostim or standard of care in patients with immune thrombocytopenia." New England Journal of Medicine 363.20 (2010): 1889-1899.

-Kuter, David J. "The biology of thrombopoietin and thrombopoietin receptor agonists." International journal of hematology 98 (2013): 10-23.

-Kuter, David J., et al. "Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies." British Journal of Haematology 185.3 (2019): 503-513.

-Bussel, James B., and Mariana P. Pinheiro. "Eltrombopag." Hematopoietic Growth Factors in Oncology (2010): 289-303.

-Erickson-Miller, Connie L., et al. "Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist." Stem cells 27.2 (2009): 424-430.

-Jurczak, Wojciech, et al. "Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia." British journal of haematology 183.3 (2018): 479-490.

-Cooper, Nichola, et al. "Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel." Acta Haematologica 144.4 (2021): 418-426.

-Zaja, F., et al. "Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations." Blood Reviews 41 (2020): 100647.

-González-López, Tomás José, et al. "Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia." Platelets 26.1 (2015): 83-86.

-Provan, D., et al. "Sustained responses following treatment with romiplostim in immune thrombocytopenia: a single-centre experience." J Hematol Thromboembolic Dis 2.04 (2014): 1-3.

-Ghadaki, Bahareh, et al. "Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists." Transfusion 53.11 (2013): 2807-2812.

-Scheinberg, Phillip. "Activity of eltrombopag in severe aplastic anemia." Blood Advances 2.21 (2018): 3054-3062.

-Bussel, James, et al. "Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo‐controlled trials." American journal of hematology 93.7 (2018): 921-930.

-Bussel, James B., et al. "Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program." American journal of hematology 94.5 (2019): 546-553.

-Jaime-Pérez, José Carlos, et al. "Insights on chronic immune thrombocytopenia pathogenesis: a bench to bedside update." Blood Reviews 49 (2021): 100827.

-Newland, Adrian C., et al. "Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia." American journal of hematology 95.2 (2020): 178-187.

-Zuercher, Adrian W., et al. "Next-generation Fc receptor–targeting biologics for autoimmune diseases." Autoimmunity reviews 18.10 (2019): 102366.

-Langrish, Claire L., et al. "Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease." The Journal of Immunology 206.7 (2021): 1454-1468.

-Gavriilaki, Eleni, Régis Peffault de Latour, and Antonio Maria Risitano. "Advancing therapeutic complement inhibition in haematologic diseases: PNH and beyond." Blood, The Journal of the American Society of Hematology 139.25 (2022): 3571-3582.

-Cheloff, Abraham Z., David J. Kuter, and Hanny Al‐Samkari. "Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features." Research and Practice in Thrombosis and Haemostasis 4.5 (2020): 807-812.

-Ulrichts, Peter, et al. "Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans." The Journal of Clinical Investigation 128.10 (2018): 4372-4386.

-Robak, Tadeusz, et al. "Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia." Blood advances 4.17 (2020): 4136-4146.

-Crickx, Etienne, et al. "Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia." Haematologica 106.12 (2021): 3198.




DOI: http://dx.doi.org/10.52155/ijpsat.v43.1.5963

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Maged Naser

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.